WallStreetZenWallStreetZen

NASDAQ: ATRA
Atara Biotherapeutics Inc Stock

$0.66-0.03 (-4.35%)
Updated Nov 30, 2023
ATRA Price
$0.66
Fair Value Price
$1.13
Market Cap
$67.27M
52 Week Low
$0.20
52 Week High
$5.64
P/E
-0.24x
P/B
-1.32x
P/S
34.67x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.54M
Earnings
-$290.25M
Gross Margin
-26.1%
Operating Margin
-6,321.05%
Profit Margin
-6,390.3%
Debt to Equity
-4.71
Operating Cash Flow
-$199M
Beta
1.67
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ATRA Overview

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ATRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ATRA ($0.66) is undervalued by 41.53% relative to our estimate of its Fair Value price of $1.13 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ATRA ($0.66) is significantly undervalued by 41.53% relative to our estimate of its Fair Value price of $1.13 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ATRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ATRA due diligence checks available for Premium users.

Be the first to know about important ATRA news, forecast changes, insider trades & much more!

ATRA News

Valuation

ATRA fair value

Fair Value of ATRA stock based on Discounted Cash Flow (DCF)
Price
$0.66
Fair Value
$1.13
Undervalued by
41.53%
ATRA ($0.66) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATRA ($0.66) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ATRA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.24x
Industry
12.22x
Market
29.24x

ATRA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-1.32x
Industry
5.4x

ATRA's financial health

Profit margin

Revenue
$2.1M
Net Income
-$69.8M
Profit Margin
-3,264.6%
ATRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ATRA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$188.8M
Liabilities
$239.6M
Debt to equity
-4.71
ATRA's short-term assets ($118.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATRA's long-term liabilities ($160.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATRA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$51.3M
Investing
$70.4M
Financing
-$208.0k
ATRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ATRA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ATRA$67.27M-4.62%-0.24x-1.32x
AFMD$67.20M-13.46%-0.54x0.83x
TPST$67.65M+5.56%-1.60x-56.85x
BIVI$67.94M-8.16%-1.24x9.00x
ADCT$68.27M+7.79%-0.38x-1.26x

Atara Biotherapeutics Stock FAQ

What is Atara Biotherapeutics's quote symbol?

(NASDAQ: ATRA) Atara Biotherapeutics trades on the NASDAQ under the ticker symbol ATRA. Atara Biotherapeutics stock quotes can also be displayed as NASDAQ: ATRA.

If you're new to stock investing, here's how to buy Atara Biotherapeutics stock.

What is the 52 week high and low for Atara Biotherapeutics (NASDAQ: ATRA)?

(NASDAQ: ATRA) Atara Biotherapeutics's 52-week high was $5.64, and its 52-week low was $0.20. It is currently -88.3% from its 52-week high and 231.66% from its 52-week low.

How much is Atara Biotherapeutics stock worth today?

(NASDAQ: ATRA) Atara Biotherapeutics currently has 101,922,250 outstanding shares. With Atara Biotherapeutics stock trading at $0.66 per share, the total value of Atara Biotherapeutics stock (market capitalization) is $67.27M.

Atara Biotherapeutics stock was originally listed at a price of $10.65 in Oct 16, 2014. If you had invested in Atara Biotherapeutics stock at $10.65, your return over the last 9 years would have been -93.8%, for an annualized return of -26.58% (not including any dividends or dividend reinvestments).

How much is Atara Biotherapeutics's stock price per share?

(NASDAQ: ATRA) Atara Biotherapeutics stock price per share is $0.66 today (as of Nov 30, 2023).

What is Atara Biotherapeutics's Market Cap?

(NASDAQ: ATRA) Atara Biotherapeutics's market cap is $67.27M, as of Dec 2, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Atara Biotherapeutics's market cap is calculated by multiplying ATRA's current stock price of $0.66 by ATRA's total outstanding shares of 101,922,250.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.